Desmopressin (DDAVP) improves recruitment of activated platelets to collagen but simultaneously increases platelet endothelial interactions in vitro

References

• Frenette PS, Denis CV, Weiss L, Jurk K, Subbarao S, Kehrel B, Hartwig JH, Vestweber D, Wagner DD. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med 2000; 191: 1413–1422
   PubMed Web of Science ®Google Scholar
• Turitto VT, Baumgartner HR. Platelet interaction with subendothelium in a perfusion system: Physical role of red blood cells. Microvasc Res 1975; 9: 335–344
   PubMed Web of Science ®Google Scholar
• Jones GT, van Rij A. In situ von Willebrand factor staining in human arteries and veins. Thromb Res 2000; 97: 369–374
   PubMed Web of Science ®Google Scholar
• De Meyer GR, Hoylaerts MF, Kockx MM, Yamamoto H, Herman AG, Bult H. Intimal deposition of functional von Willebrand factor in atherogenesis. Arterioscler Thromb Vasc Biol 1999; 19: 2524–2534
   PubMed Web of Science ®Google Scholar
• Theilmeier G, Michiels C, Spaepen E, Vreys I, Collen D, Vermylen J, Hoylaerts MF. Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood 2002; 99: 4486–4493
   PubMed Web of Science ®Google Scholar
• Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003; 1: 682–689
   PubMed Web of Science ®Google Scholar
• Kaufmann JE, Oksche A, Wollheim CB, Gunther G, Rosenthal W, Vischer UM. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest 2000; 106: 107–116
   PubMed Web of Science ®Google Scholar
• Schulman S. DDAVP – the multipotent drug in patients with coagulopathies. Transfus Med Rev 1991; 5: 132–144
   PubMedGoogle Scholar
• Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20 years. Blood 1997; 90: 2515–2521
   PubMed Web of Science ®Google Scholar
• Datta YH, Ewenstein BM. Regulated secretion in endothelial cells: Biology and clinical implications. Thromb Haemost 2001; 86: 1148–1155
   PubMed Web of Science ®Google Scholar
• Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: An interaction mediated by endothelial P-selectin. Proc Natl Acad Sci USA 1995; 92: 7450–7454
   PubMed Web of Science ®Google Scholar
• Hartmann S, Reinhart W. Fatal complication of desmopressin. Lancet 1995; 345: 1302–1303
   PubMed Web of Science ®Google Scholar
• Theilmeier G, Lenaerts T, Remacle C, Collen D, Vermylen J, Hoylaerts MF. Circulating activated platelets assist THP-1 monocytoid/endothelial cell interaction under shear stress. Blood 1999; 94: 2725–2734
   PubMed Web of Science ®Google Scholar
• Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL. Platelets and shear stress. Blood 1996; 88: 1525–1541
   PubMed Web of Science ®Google Scholar
• Kaufmann JE, Iezzi M, Vischer UM. Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor- and cAMP-mediated signaling. J Thromb Haemost 2003; 1: 821–828
   PubMed Web of Science ®Google Scholar
• Tomasiak M, Stelmach H, Rusak T, Ciborowski M, Radziwon P. Vasopressin acts on platelets to generate procoagulant activity. Blood Coagul Fibrinolysis 2008; 19: 615–624
   PubMed Web of Science ®Google Scholar
• Vanderwel M, Lum DS, Haslam RJ. Vasopressin inhibits the adenylate cyclase activity of human platelet particulate fraction through V1-receptors. FEBS Lett 1983; 164: 340–344
   PubMed Web of Science ®Google Scholar
• Thibonnier M, Roberts JM. Characterization of human platelet vasopressin receptors. J Clin Invest 1985; 76: 1857–1864
   PubMed Web of Science ®Google Scholar
• Ghosh S, Rao AK. Lack of effect of 1-desamino-8-D-arginine vasopressin on direct adhesion of platelets to collagen. Thromb Res 1993; 70: 417–422
   PubMed Web of Science ®Google Scholar
• Yang X, Disa J, Rao AK. Effect of 1-desamino-8-D-arginine vasopressin (DDAVP) on human platelets. Thromb Res 1990; 59: 809–818
   PubMed Web of Science ®Google Scholar
• Sloand EM, Alyono D, Klein HG, Chang P, Yu M, Lightfoot FG, Kessler C. 1-Deamino-8-D-arginine vasopressin (DDAVP) increases platelet membrane expression of glycoprotein Ib in patients with disorders of platelet function and after cardiopulmonary bypass. Am J Hematol 1994; 46: 199–207
   PubMed Web of Science ®Google Scholar
• Balduini CL, Noris P, Belletti S, Spedini P, Gamba G. In vitro and in vivo effects of desmopressin on platelet function. Haematologica 1999; 84: 891–896
   PubMed Web of Science ®Google Scholar
• Nieswandt B, Watson SP. Platelet-collagen interaction: Is GPVI the central receptor?. Blood 2003; 102: 449–461
   PubMed Web of Science ®Google Scholar
• Lethagen S. Desmopressin in mild hemophilia A: Indications, limitations, efficacy, and safety. Semin Thromb Hemost 2003; 29: 101–116
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-D-arginine vasopressin: A new pharmacological approach to the management of haemophilia and von Willebrands’ diseases. Lancet 1977; 1: 869–872
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975; 30: 81–93
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Inaba M, Miyashima S, Ogawa R, Ikehara S. A new strategy for treatment of autoimmune diseases in chimeric resistant MRL/lpr mice. Blood 1998; 91: 4616–4623
   PubMed Web of Science ®Google Scholar
• Federici AB, de Groot PG, Moia M, Ijsseldijk MJ, Sixma JJ, Mannucci PM. Type I von Willebrand disease, subtype ‘platelet low’: Decreased platelet adhesion can be explained by low synthesis of von Willebrand factor in endothelial cells. Br J Haematol 1993; 83: 88–93
   PubMed Web of Science ®Google Scholar
• Jennings LK. Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 2009; 102: 248–257
   PubMed Web of Science ®Google Scholar
• Langer HF, Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost 2008; 99: 480–486
   PubMed Web of Science ®Google Scholar
• Kanwar S, Woodman RC, Poon MC, Murohara T, Lefer AM, Davenpeck KL, Kubes P. Desmopressin induces endothelial P-selectin expression and leukocyte rolling in postcapillary venules. Blood 1995; 86: 2760–2766
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Nagura H, Kaneda T. DDAVP and epinephrine-induced changes in the localization of von Willebrand factor antigen in endothelial cells of human oral mucosa. Blood 1988; 72: 850–854
   PubMed Web of Science ®Google Scholar
• Andre P, Denis CV, Ware J, Saffaripour S, Hynes RO, Ruggeri ZM, Wagner DD. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood 2000; 96: 3322–3328
   PubMed Web of Science ®Google Scholar
• Tomokiyo K, Kamikubo Y, Hanada T, Araki T, Nakatomi Y, Ogata Y, Jung SM, Nakagaki T, Moroi M. von Willebrand factor accelerates platelet adhesion and thrombus formation on a collagen surface in platelet-reduced blood under flow conditions. Blood 2005; 105: 1078–1084
   PubMed Web of Science ®Google Scholar
• Solomon C, Budde U, Schneppenheim S, Czaja E, Hagl C, Schoechl H, von Depka M, Rahe-Meyer N. Acquired type 2A von Willebrand syndrome caused by aortic valve disease corrects during valve surgery. Br J Anaesth 2011; 106: 494–500
   PubMed Web of Science ®Google Scholar
• Hanke AA, Dellweg C, Kienbaum P, Weber CF, Gorlinger K, Rahe-Meyer N. Effects of desmopressin on platelet function under conditions of hypothermia and acidosis: An in vitro study using multiple electrode aggregometry. Anaesthesia 2010; 65: 688–691
   PubMed Web of Science ®Google Scholar
• Carless PA, Henry DA, Moxey AJ, O’Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D. Desmopressin for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2004; 1: CD001884
   Google Scholar
• Gurusamy KS, Li J, Sharma D, Davidson BR. Pharmacological interventions to decrease blood loss and blood transfusion requirements for liver resection. Cochrane Database Syst Rev 2009; 4: CD008085
   Google Scholar
• Trigg DE, Stergiotou I, Peitsidis P, Kadir RA. A systematic review: The use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy. Haemophilia 2012; 18: 25–33
   PubMed Web of Science ®Google Scholar
• Prohaska W, Zittermann A, Luth JU, Inoue K, Koster-Eiserfunke W, Baller D, Korfer R, Kleesiek K. Prevalent platelet dysfunction in patients with aortic valve disease. J Heart Valve Dis 2008; 17: 542–547
   PubMed Web of Science ®Google Scholar
• Vincentelli A, Susen S, Le Tourneau T, Six I, Fabre O, Juthier F, Bauters A, Decoene C, Goudemand J, Prat A, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349: 343–349
   PubMed Web of Science ®Google Scholar
• Yoshida K, Tobe S, Kawata M. Acquired von Willebrand disease type IIA in patients with aortic valve stenosis. Ann Thorac Surg 2006; 81: 1114–1116
   PubMed Web of Science ®Google Scholar
• Weber CF, Dietrich W, Spannagl M, Hofstetter C, Jambor C. A point-of-care assessment of the effects of desmopressin on impaired platelet function using multiple electrode whole-blood aggregometry in patients after cardiac surgery. Anesth Analg 2010; 110: 702–707
   PubMed Web of Science ®Google Scholar